Drugs / A244d11 gp120
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06484335 | Mar 2025 → Jul 2029 expected | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A244d11 gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06484335 ↗ |
| Modality | Protein / enzyme biologic | “gp120 envelope glycoprotein” NCT05769569 ↗ |
| Route | Intramuscular | “will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.” NCT05769569 ↗ |